At a glance
- Originator Boehringer Ingelheim
- Class Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 18 Jun 2001 No-Development-Reported for Inflammation in USA (Unknown route)
- 08 Dec 1997 New profile
- 08 Dec 1997 Preclinical development for Inflammation in USA (Unknown route)